A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors

NCT05143970 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Cancer
Metastatic Breast Cancer
Metastatic Pancreatic Cancer
Metastatic Gastric Cancer
Metastatic Lung Cancer
Metastatic Ovary Cancer
Oesophageal Cancer
Endometrial Cancer
Advanced Solid Tumor

Interventions

DRUG: IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB

Sponsor

Institut Paoli-Calmettes

Collaborators

[object Object]